ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1237

Baseline Evaluation of Insulin Resistance in Patients with early Non-Treated Rheumatoid Arthritis

Sara Manrique-Arija1, María América López-Lasanta2, Pilar Espiño- Lorenzo2, Pedro Valdivielso3, José Rioja3, Inmaculada Ureña1, Francisco Gabriel Jimenez- Núñez1, Carmen M. Romero-Barco1, Veronica Rodríguez-García1, Laura Nieves2, Mari Carmen Ordoñez-Cañizares2, Laura Cano2, Maria Victoria Irigoyen2 and Antonio Fernández-Nebro4, 1Rheumatology, Hospital Carlos Haya. University of Malaga, Malaga, Spain, 2Hospital Carlos Haya. University of Malaga, Malaga, Spain, 3Department of Medicine. University of Malaga, Malaga, Spain, 4Rheumatology, Hospital Carlos Haya. University of Malaga. IBIMA, Malaga, Spain

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: cytokines, Inflammation, insulin resistance and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects II: Clinical Features & Comorbidity/Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: High levels of inflammatory cytokines are associated with insulin resistance syndrome in long-standing AR. The aim was to analyze insulin resistance (IR), adipokines, inflammatory cytokines and baseline clinical and laboratory features in patients with early rheumatoid arthritis (ERA) who have not received any treatment for their underlying disease.

Methods: Cross-sectional, case-control, study. Forty-six consecutively patients with ERA (disease duration <1 year) according to 2010 ACR/EULAR criteria, older than 16 years of age and 45 sex and age-matched controls were included. Patients with Diabetes (2010 ADA Criteria) and in prior or current treatment with DMARDs or corticosteroids were excluded. All participants signed an informed consent. Baseline blood and urine samples were collected; Glucose, lipid profile, RF, anti-CCP, ESR, CRP and other parameters were measured in fresh samples; serum was stored at -80°C for later analysis of insulin, ultrasensitive CRP, IL6, TNFα, resistin, adiponectin y leptin. Insuline resistance was estimated by the Homeostasis model assesment for insulin resistance (HOMA-IR), HOMA β, McAuley and QUICKI index. A cardiovascular risk factors (CVRF) questionnaire and a dietary survey were also completed. Measurement of abdominal and hip circumference was performed. Statistical analysis: T-test or Mann Whitney test and Pearson or Spearson´s correlation analysis were performed.

Results: Among 103 subjects twelve were excluded (6 were other types of arthritis, 6 had type 2 diabetes) and finally, 91 subjects were included; 46 had RA (50.5%) and 45 were healthy controls (49.5%). Most of them were women (~76%) and there were not differences in age, sex and BMI, between groups but hypertension was higher in patients than controls (30 vs 13%, p < 0.05). Regarding baseline characteristics of patients with RA, the average time of evolution of RA was 6 months, and more than 70% had positive RF and anti-CCP. Concerning laboratory parameters, CRP and ESR were higher in RA patients than in controls (p<0,001). In relation to CVRF and IR, total cholesterol was higher in controls [215 (SD±40,3) mg/dl vs 195(SD±39,5) mg/dl (p< 0,05) ], and HDL cholesterol lower in RA patients [52(SD±14,8)mg/dl Vs 59 (SD±16,7) mg/dl(p< 0,05)], and also levels of cytokines such as IL6, TNF-alpha and Resistin in blood were higher in patients than controls. No statistically significant differences were found in leptin, adiponectin or atherogenic index between cases and controls neither in insulin resistance estimated by HOMA-RI, HOMA β ,QUICKI nor McAuley. Bivariate analysis revealed a statistically significant correlation between the different indices of IR and parameters of inflammatory activity (PCR, TNF), leptin and body composition.

Conclusion: Although patients showed higher blood pressure, total cholesterol and resistin levels and lower HDL cholesterol than age, sex and BMI matched controls, we were unable to show differences in leptin, adiponectin and any of the insulin resistance indexes assessed, in spite of the expected high levels of systemic inflammatory molecules, such as TNFα and IL-6 in patients group.  Lack of association between AR and IR indexes might be due to the short course of the disease.


Disclosure:

S. Manrique-Arija,
None;

M. A. López-Lasanta,
None;

P. Espiño- Lorenzo,
None;

P. Valdivielso,
None;

J. Rioja,
None;

I. Ureña,
None;

F. G. Jimenez- Núñez,
None;

C. M. Romero-Barco,
None;

V. Rodríguez-García,
None;

L. Nieves,
None;

M. C. Ordoñez-Cañizares,
None;

L. Cano,
None;

M. V. Irigoyen,
None;

A. Fernández-Nebro,

Junta de Andalucia,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baseline-evaluation-of-insulin-resistance-in-patients-with-early-non-treated-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology